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Malignant tumor of the temporal bone shows a clinically aggressive course, and 
prognosis has remained poor despite recent advances in surgical strategies, radiotherapy 
and chemotherapy. This poor prognosis has been attributed to a complicated anatomy 
and to its proximity to the dura mater and nearby neural and vascular structures. These 
important structures are all close to the bone in the external auditory canal (EAC) and 
middle ear (ME). Bone involvement by the malignant tumor can thus be the key to the 
prognosis. Many reports have tried to evaluate survival in this aggressive disease, but 
patient numbers have been limited due to the rarity of this disease.(1-9) We encountered 
16 cases of primary squamous cell carcinoma (SCC) of the temporal bone between 2001 
and 2006, and evaluated prognostic factors associated with the survival rate for SCC of 
the temporal bone. As expected, extensive bone erosion correlated with a worse 
prognosis of SCC of the temporal bone, whereas extensive soft tissue involvement did 
not correlate with prognosis.(10) We subsequently wondered why extensive bone 
erosion was associated with poor prognosis. This question led us to suspect that 
epithelial-mesenchymal transition (EMT) is associated with extensive bone erosion in 
SCC of the temporal bone. 
EMT is a process whereby epithelial cells lose polarity and cell-to-cell adhesions and 
undergo dramatic remodeling of the cytoskeleton.(11) Concurrent with loss of epithelial 
cell adhesion and cytoskeletal components, cells undergoing EMT acquire expression of 
mesenchymal components and gain a migratory phenotype. Wound healing and 
progression of carcinoma to invasive and metastatic phenotypes also involve localized 
EMT. EMT was first recognized during embryogenesis in the early 1980s. 
Accumulating evidence suggests that carcinoma cells activate a dormant EMT program 
to promote cell migration, invasion, and metastasis.(11-13) To date, no reports 
concerning EMT in malignant tumor of the temporal bone appear to have been 
published. The present study therefore used immunohistochemical methods to analyze 
expressions of EMT in patients with SCC of the temporal bone and studied the 
association between EMT and prognosis. We also investigated correlations between 
EMT and extensive bone erosion. 
Transforming growth factor (TGF)- is a growth factor that has been demonstrated to 
trigger EMT and to promote the invasive ability of many epithelial cells in vitro.(14) 
These phenomena suggested a possible role of TGF- in EMT for SCC of the temporal 
bone. We therefore also performed immunohistochemical analyses to clarify 
correlations between TGF- and EMT in SCC of the temporal bone, and investigated 
the mechanisms by which EMT might be induced by TGF-. 
 
MATERIALS AND METHODS 
Patients 
We studied 16 patients with primary cancer of the EAC and ME for whom 
pathological materials and adequate medical records and follow-up data were available. 
A total of 16 patients (7 men, 9 women) underwent treatment at Kanazawa University 
Hospital (Kanazawa, Japan) between 2001 and 2006. The mean age of patients at first 
presentation was 64 years (range, 41-83 years). Tumors of the 16 patients were staged 
according to the revised Pittsburgh staging system (Table 1). They include three T1, two 
T2, three T3, and eight T4 patients. Thirteen patients were treated with surgical 
resection. The surgical resection performed most often was lateral temporal bone 
resection (LTBR). LTBR was performed combined with radiotherapy for tumors that 
remained lateral to the tympanic membrane. Three patients with T4 disease received 
chemo-radiation therapy alone because their tumors showed extensive invasion of dura 
matter and major vessels. Six patients in the T4 group and all patients in the T3 group 
showed extensive bone involvement, including T4 with bone erosion of the deep 
temporal bone and T3 with apparent bone erosion of the external auditory canal and/or a 
tumor involving the middle ear cavity. Classification of the tumors was based on CT 
and MRI analysis. The degree of bone involvement is described in detail below (the 
numbers correspond to the patient numbers shown in Table 2): 6, erosion of the osseous 
external auditory canal (full thickness). 7, erosion of the osseous external auditory canal 
(full thickness) 8, erosion of the osseous external auditory canal (full thickness) and a 
tumor involving the middle ear cavity. 9, bone erosion of the deep temporal bone  
involving dura. 12 erosion of carotid canal , involvement of the temporal bone and 
mandibula, erosion of the osseous external auditory canal (full thickness) 13, erosion of 
carotid canal and the jugular foramen. erosion of the osseous external auditory canal 
(full thickness) 14, bone erosion of the deep temporal bone ,involving dura and the 
middle wall of the middle ear ,evidence of facial paresis. 15, bone erosion of the deep 
temporal bone, involving dura and evidence of facial paresis. 16, erosion of dura and the 
carotid canal. erosion of the osseous external auditory canal (full thickness) 
All medical records were retrospectively reviewed for collection and evaluation of 
data regarding age, sex, presenting symptoms, findings from computed tomography 
(CT), TNM status at the time of operation, type and extent of operation, histological 
diagnosis, adjunctive therapy (postoperative radiotherapy, chemotherapy), sequelae, and 
treatment outcomes. The period from symptom onset to diagnosis was unknown for four 
patients (1, 3, 6, 14); one month for four patients (2, 7, 9, 13), two months for three 
patients (5, 11, 12), three months for two patients (10, 16), five months for one patient 
(4), and seven months for two patients (8, 14). 
 
Single immunostaining of TGF- and vimentin 
The various protein expressions were visualized using an indirect immunoperoxidase 
technique. Paraffin-embedded blocks of specimens were cut into 5-μm-thick serial 
sections. After deparaffinization, sections were treated with methanol containing 3% 
hydrogen peroxide for 10 min. After blocking the endogenous peroxidase, sections were 
incubated in protein block solution (Dako Cytomation, Glostrup, Denmark) for 30 min, 
then incubated overnight at 4°C with each primary antibody. We applied the following 
primary antibodies: vimentin (NeoMarkers Ab-2 V9; Thermo Scientific,(USA), TGF-1 
v  (SANTA CRUZ BIOTECHNOLOGY inc, Europe) The dilutions used were each 
1:100. The sections were next incubated for 1 h at room temperature with goat 
anti-mouse immunoglobulins (Igs), which were conjugated to peroxidase-labeled 
polymer (Envision; Dako Cytomation). We used 3,3'-diaminobenzidine 
tetrahydrochloride as the chromogen, followed by light counterstaining with 
hematoxylin. Negative controls were evaluated by substituting the primary antibody 
with similarly diluted non-immunized mouse serum. 
 
Dual-fluorescent immunostaining of TGF- and vimentin 
SCC in temporal bone specimens expressing both TGF- and vimentin were used for 
dual-fluorescent immunostaining, to clarify the location of cancer cells expressing 
vimentin. Deparaffinized sections were treated with methanol containing 3% hydrogen 
peroxide for 10 min. 
Specimens were incubated with antibodies to TGF- and vimentin (the same 
antibodies used in single immunostaining) overnight at 4°C. The reaction product was 
visualized with fluorescent goat anti-mouse and anti-rabbit IgG antibodies  (1:500; 
Molecular Probes, Eugene, OR, USA). Specimens were counterstained using Prolong 
Gold antifade reagent with DAPI (Invitrogen Molecular Probes, USA) and were 
observed under a microscope (ECLIPSE E1000M; Nikon, Japan). No positive staining 
was obtained when primary antibodies were omitted or replaced with normal mouse 
serum in the negative controls of staining procedures. 
 
Evaluation of specimens 
For each of the immunohistochemical markers studied, the number of 
immunoreactive cells was calculated using an image analysis system (ACT-1C for 
DXM1200C; Nikon). Specimens were evaluated independently by two of the authors 
that were blinded to the clinical data, and were then reviewed by the other authors. Two 
examiners each selected four representative fields, with each field containing more than 
200 tumor cells. Both the number of immunoreactive cells and the total number of 
tumor cells were counted, and calculated expression scores. At least 800 tumor cells 
were counted and evaluated by each examiner. 
 
Data analysis 
Survival rates were estimated using Kaplan-Meier methods, and outcomes were 
analyzed using Windows personal computers and PASW Statistics 18 (SPSS Japan Inc, 
IBM company). Log-rank testing for two related samples was used to compare means of 
the paired variables, with values of P<.05 considered significant. The increased 
vimentin expression score in patients with extensive bone involvement was examined 
using the Mann-Whitney U test, with values of P<.05 considered significant. 
 
RESULTS 
Vimentin was expressed on temporal bone tumor cells 
Medical records were reviewed retrospectively for all of the 16 patients with primary 
SCC of the EAC (n=13) and ME (n=3) (Table 2). Tumor cells clearly showed an 
all-or-nothing pattern for expression of vimentin (Fig. 1), with all expression scores 
either  >10% or <1%. Outcomes of vimentin staining in tumor cells were classified as 
either positive (expression score >10%; n=9) or negative (expression score <1%; n=7). 
Patients showing vimentin-positive tumor cells were regarded as EMT-positive, as gain  
of vimentin has been reported as a hallmark of EMT for several types of cancer. 
 
Correlation of Vimentin staining in temporal bone SCC with prognosis 
Figure 2 shows Kaplan-Meier survival curves for disease-specific survival (DSS) in 
patients with and without EMT. No significant differences were seen using log-rank 
testing. 
 
Vimentin expression correlated significantly with extensive bone involvement 
We tried to analyze correlations between the vimentin expression score and bone 
invasion. Interestingly, a significant increase in the vimentin expression score was seen 
in patients with extensive bone involvement (P<.05) (Fig. 3). 
 
TGF-1-positive cells were seen in the same section of the vimentin-positive areas 
Figure 4 shows double staining of TGF-1 and vimentin in temporal bone tumor cells. 
TGF-1-positive cells were seen in the same areas as vimentin-positive cells, but were 
not totally co-localized. We examined 9 vimentin-positive cases using the same methods 
and revealing the same findings. 
 
DISCUSSION 
In the process of embryonic development, epithelial cells often lose their epithelial 
features and present with a mesenchymal phenotype, a phenomenon known as EMT. 
This process is important during fetal development, wound repair and tissue remodeling, 
allowing epithelial cells to acquire fibroblast-like properties, reducing intracellular 
adhesion and increasing motility. EMT may be a mechanism by which epithelial cells 
acquire the ability to migrate, and this process is normally under tight control. Several 
recent studies have suggested that EMT might be involved in the invasion and 
metastasis of malignant tumors, and whether EMT plays a role in metastatic behaviors 
remains unclear. 
This study tried to investigate the role of EMT in SCC of the temporal bone. First, we 
studied associations between EMT and prognosis. Immunohistochemical analysis 
demonstrated that gain of vimentin in tumor cells tended to correlated with poor clinical 
outcomes for SCC of the temporal bone (Fig. 2), but no significant differences were 
identified. Our previous study showed that extensive bone involvement significantly 
correlated with worse prognosis (10) We therefore examined the correlation between 
bone involvement and EMT. Interestingly, the present study showed a significant 
increase in vimentin expression among patients with extensive bone involvement 
(p<0.05) (Fig. 3). We were unable to show a direct correlation between EMT and 
prognosis, but this may be due to the rarity of the disease, with only 16 cases in this 
study. Investigation of more cases may thus confirm a direct correlation. 
On the other hand, TGF-1 has been demonstrated to trigger EMT in vitro, and is 
overexpressed in many malignant human tumors, including SCC. Overexpression of 
TGF-1 at the early stages of carcinogenesis provides tumor-suppressive effects 
primarily via growth inhibition, whereas TGF-1 overexpression at late stages of 
carcinogenesis promotes tumor progression, metastasis, and EMT, potentially via loss of 
adhesion molecules, angiogenesis, proteinase activation, and immune suppression.(15) 
In SCC of the temporal bone, EMT is expected to be induced by TGF-1. Bone is 
known to include abundant TGF-1 and the EAC and ME are bony structures. TGF-1 
released from destroyed bone after SCC invasion may thus induce EMT in temporal 
bone. This theory is consistent with the correlation we identified between bone erosion 
and EMT. In the present study, a large difference in five-year survival rate was observed 
between early-stage (T1 and T2; five-year survival rate, 80%) and late-stage (T3 and 
T4; 45%) tumors, indicating that late-stage primary squamous cell carcinoma of the 
temporal bone follows an extremely aggressive course. This may be related to the 
aforementioned increase in tumor malignancy caused by the release of TGF1 due to 
bone involvement as well as to the associated induction of EMT. In addition, in this 
study, double-staining of EMT-positive SCC cells demonstrated that TGF--positive 
areas occurred in the same areas showing vimentin gains, although exact colocalization 
was not identified. This may indicate that TGF-1 is released from the tumor cells 
themselves. This phenomenon implies that in progressive SCC of the temporal bone, 
TGF-1 that is both released from destroyed bone and secreted from the tumor cells 
themselves would induce EMT. However, the exact mechanisms underlying the 
induction of EMT remain yet to be elucidated. 
 
CONCLUSION 
This study showed significant correlations in EMT with extensive bone involvement. 
The results suggest that EMT correlates with poor prognosis for SCC of the temporal 
bone, and that this correlation is an indirect relationship resulting from the promotion of 
bone invasion by EMT. In addition, investigation of EMT in biopsy specimens before 
treatment may help in the estimation of bone involvement and prognosis. Such analyses 
might help in drafting better strategies. 
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 Fig1  Immunohistochemical staining of vimentin in squamous cell carcinoma 
of the temporal bone. A) Including vimentin-positive tumor cells and B) All cells are 
negative for vimentin.  
 
Fig2  Kaplan-Meier survival curves of disease-specific survival for patients with or 
without EMT. Statistically did not show significant increase.  
 
Fig3  A statistically significant increase of vimentin expression score was seen in 
patients with extensive bone involvement (p<0.05)  
 
Fig4  Double staining of TGFβ1 and vimentin in temporal bone tumor cells. TGFβ1 
positive cells were seen in the same section of the vimentin positive areas.  
 
 
Table 1. University of Pittsburgh staging system (Moody’s modified) for squamous cell carcinoma of the external auditory canal 
 
T status 
T1: tumor limited to the external auditory canal without bony erosion or evidence of soft tissue involvement 
T2: tumor with limited external auditory canal bony erosion (not full-thickness), or limited (<0.5 cm) soft tissue involvement 
T3: tumor eroding the osseous external auditory canal (full-thickness) with limited (<0.5 cm) soft tissue involvement, or tumor 
involving middle ear and/or mastoid 
T4: tumor eroding the cochlea, petrous apex, medial wall of middle ear, carotid canal, jugular foramen, or dura, or with extensive 
(≥0.5 cm) soft tissue involvement, such as involvement of temporomandibular joint or styloid process, or evidence of facial 
paresis 
N status 
Lymph node involvement is a poor prognostic sign; any node involvement should automatically be considered as advanced stage, ie, 
T1N1 = stage III and T2, 3, 4 N1 = stage IV 
M status 
Distant metastases indicate a very poor prognosis and should be considered as stage IV disease 
 




 Table 2. Summary of 16 patients with squamous cell carcinoma of the temporal bone 
Patient No Location  Age/Sex  Stage   Extensive bone involvement    Treatment    Outcome   Follow-up(months)   EMT 
1      EAC   79/M    T1N0              No              S＋XRT  ND      87               － 
2      EAC   77/F    T1N0              No              S      ND      44               － 
3      EAC   74/F    T1N0              No              S＋XRT  ND      38               － 
4      EAC   49/M    T2N0              No              S＋XRT  ND      30               － 
5      EAC   55/F    T2N0              No              S＋XRT      DOD      17               － 
6      EAC   69/M    T3N0              Yes              S＋XRT  ND      65               ＋ 
7      EAC   63/M    T3N0              Yes              S＋XRT      ND      33               ＋ 
8      EAC   70/M    T3N0              Yes              S＋XRT      DOD      28               ＋ 
9      ME     72/F    T4N0              Yes              S           ND      60               ＋ 
10      EAC   39/M    T4N0              No              S＋XRT  ND      47               － 
11      EAC   50/F    T4N0              No              S＋XRT  ND      32               ＋ 
12      EAC   60/F    T4N1              Yes              S＋XRT  DOD      21               ＋ 
13      EAC   41/F    T4N0              Yes              S＋XRT  DOD      13               ＋ 
14      ME     83/F    T4N0              Yes                 XRT  DOD      12               － 
15      ME     65/M   T4N0              Yes                 XRT  DOD      12               ＋ 
16     EAC    78/F    T4N0              Yes                 XRT  DOD       8               ＋ 
 
EAC, external auditory canal; ME, middle ear; S, surgery; XRT, radiation therapy; ND, no desease ; DOD, dead of disease 
 




